Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 15;23(1):1235.
doi: 10.1186/s12885-023-11733-1.

Clinical features and prognosis of cardiac metastatic tumors

Zhongqiao Lin #  1   2 , Huazhen Xiao #  3 , Jun Liu  4   2 , Ling Chen  4   2 , Huishan Zhang  1   2 , Yufang Huang  4   2 , Yu Chen  5   6 , Jing Lin  7   8
Affiliations

Clinical features and prognosis of cardiac metastatic tumors

Zhongqiao Lin et al. BMC Cancer. .

Abstract

Background: This study aimed to explore the clinical features and prognosis of cardiac metastatic tumors. In addition, whether continuing antitumor therapy after the development of cardiac metastases can benefit patients and the response of cardiac metastases were investigated.

Methods: A retrospective analysis was conducted on patients with malignancies who were admitted to Fujian Cancer Hospital and Fujian Provincial Hospital from January 2007 to September 2022, and the follow-up period ended in March 2023. Clinical data were gathered, treatment efficacy was evaluated, and survival analysis was performed.

Results: After the patients developed cardiac metastasis, the overall 30-day, 3-month, 6-month, and 12-month survival rates were 85.00%, 59.00%, 51.00% and 38.00%, respectively. With continued treatment, the average survival time was 27.33 months (95% confidence interval [CI]: 16.88-37.79), which exceeded the 6.6 months (95% confidence interval [CI]: 0.03-13.69) observed for patients who withdrew from treatment (P < 0.001). The responses of cardiac metastases corresponded to the responses of the primary tumors. Patients with a cardiac response had a median survival time of 55.60 months, which exceeded the 13.40 months observed for those without a cardiac response. However, there was no significant difference (P = 0.375).

Conclusions: In conclusion, continuing antitumor therapy after the development of cardiac metastases can significantly prolong patient survival. Cardiac metastases and primary tumors respond consistently to antitumor treatment. The risk of death due to heart failure in cancer patients with cardiac metastases needs to be further investigated.

Keywords: Cancer survivorship; Cardiac function; Cardiac metastasis; Echocardiography; Efficacy evaluation; Tumor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Overall survival after the development of cardiac metastases
Fig. 2
Fig. 2
Effect of continuation or discontinuation of treatment on survival after cardiac metastasis development
Fig. 3
Fig. 3
Effect of cardiac response on survival after cardiac metastasis development
See this image and copyright information in PMC

References

    1. Ren DY, Fuller ND, Gilbert SAB, Zhang Y. Cardiac tumors: clinical perspective and therapeutic considerations. Curr Drug Targets. 2017;18(15):1805–1809. doi: 10.2174/1389450117666160703162111. - DOI - PubMed
    1. Cresti A, Chiavarelli M, Glauber M, Tanganelli P, Scalese M, Cesareo F, Guerrini F, Capati E, Focardi M, Severi S. Incidence rate of primary cardiac tumors: a 14-year population study. J Cardiovasc Med (Hagerstown) 2016;17(1):37–43. doi: 10.2459/JCM.0000000000000059. - DOI - PubMed
    1. Tyebally S, Chen D, Bhattacharyya S, Mughrabi A, Hussain Z, Manisty C, Westwood M, Ghosh AK, Guha A. Cardiac tumors: jacc cardiooncology state-of-the-art review. JACC CardioOncol. 2020;2(2):293–311. doi: 10.1016/j.jaccao.2020.05.009. - DOI - PMC - PubMed
    1. Butany J, Leong SW, Carmichael K, Komeda M. A 30-year analysis of cardiac neoplasms at autopsy. Can J Cardiol. 2005;21(8):675–680. - PubMed
    1. Sarjeant JM, Butany J, Cusimano RJ. Cancer of the heart: epidemiology and management of primary tumors and metastases. Am J Cardiovasc Drugs. 2003;3(6):407–421. doi: 10.2165/00129784-200303060-00004. - DOI - PubMed

LinkOut - more resources